Objective: The purpose of this article is to review the utility of 18F-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. COnclusion: Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning. Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.
|Original language||English (US)|
|Number of pages||10|
|Journal||American Journal of Roentgenology|
|State||Published - Aug 2020|
- Prostate cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging